September 29, 2020

Anti-C5a Antibody IFX-1 (Vilobelimab) Treatment versus Best Supportive Care for Patients with Severe COVID-19 (PANAMO): An Exploratory, Open-Label, Phase 2 Randomised Controlled Trial

Category: Article Summary

Topic: Testing and Treatment

Keywords (Tags): treatment

• An exploratory, open-label, phase 2 randomized trial of the monoclonal antibody IFX-1 (vilobelimab) in adults with severe COVID-19 indicated that C5a inhibition with the drug appeared to be safe. Mortality estimates at 28 days were 13% for the IFX-1 group and 27% for the control group, although the authors note that this outcome is preliminary and the study lacked sufficient power for this endpoint. The frequency of serious adverse events were similar between groups, and no deaths were considered related to treatment assignment. However, a smaller proportion of patients had serious pulmonary embolisms in the IFX-1 group (13%) than in the control group (40%).

Vlaar et al. (Sept 2020). Anti-C5a Antibody IFX-1 (Vilobelimab) Treatment versus Best Supportive Care for Patients with Severe COVID-19 (PANAMO): An Exploratory, Open-Label, Phase 2 Randomised Controlled Trial. The Lancet Rheumatology. https://doi.org/10.1016/S2665-9913(20)30341-6